Tirzepatide (Zepbound, Mounjaro) produces 22.5% average weight loss and is the closest approved analog to retatrutides efficacy level
But the system treats compounding like a loophole instead of a lifeline, he added
The GLP-1 and GIP components function similarly to tirzepatide, providing appetite suppression, improved insulin dynamics, and reduced caloric intake
The main benefits of GLP-1 therapy include: Enhanced insulin secretion in response to meals Reduced glucagon release, preventing high blood sugar levels Slowed gastric emptying, leading to prolonged satiety Decreased appetite, which may help with weight loss Currently available GLP-1 receptor agonists include drugs like liraglutide (Victoza), semaglutide (Ozempic, Wegovy), exenatide (Byetta), and dulaglutide (Trulicity)
doi: 10.1186/s12883-022-02723-0